Notably, while bibliometric studies on the PD-1/PD-L1 signaling axis or CAR-T cell therapies have been reported (18), there remains a lack of comprehensive and systematic analyses specifically focused on the field of tumor immune escape. Here, RPL17 is linked to neoplasm.